The following initiatives were funded since 2010.
FCF has funded the creation of The Fibrolamellar Consortium. This is a collaborative effort by Memorial Sloan- Kettering (NYC), Johns Hopkins (Baltimore), University of California/San Francisco, and Dana Farber (Boston). The consortium’s mission is to:
The consortium opened a clinical trial in July 2012 testing a novel treatment designed specifically for FLC. The treatment targets certain cell-signaling pathways that appear to be overactive in this disease. This is the first clinical trial dedicated to patients with advanced FLC that cannot be treated with surgery. More information about the trial, eligibility and the specific link to this trial at clinicaltrials.gov can be found here.
The Consortium meets twice a year at the ASCO (American Society of Clinical Oncology) converntions. The Consortium had a poster presentation at the ASCO convention in Chicago, June 2011. This generated a lot of interest and queries about fibrolamellar research.
FCF has funded the first clinical trial of drugs aimed specifically at fibrolamellar liver cancer. This trial is being coordinated by Dr. Ghassan Abou-Alfa at Memorial Sloan Kettering Cancer Center (MSKCC). The trial is also at other consortium members, the University of California San Francisco, Johns Hopkins, and Dana Farber. Two major pharmaceutical companies are donating the drugs. More information about the trial, eligibility and the specific link to this trial at clinicaltrials.gov can be found here.
MSKCC is sequencing the exome of the fibrolamellar genome.
MSKCC is the coordinator of the Fibrolamellar Consortium.
The Foundation granted Dr. Sandy Simon funds to study immunotherapy and fibrolamellar. Rockefeller University has put their full support behind Dr. Simon and charges no administrative fees for this research. Rockefeller University has provided Dr. Simon with a dedicated space exclusively for fibrolamellar research, The Tucker Davis Fibrolamellar Research Facility. FCF provided a freezer for fibrolamellar tissue samples. Dr. Simon's goal is finding a cure - total eradication from the body. He feels this path is through the immune system using the patients' own antibodies to track and kill the cancer cells. His research also includes melanoma and breast cancer cells.
Dr. Simon has already discovered a way to extract antibodies from a patient, mark them, and re-introduce them into the body. The marked antibodies can attach to the smallest of cancer cells which will help surgeons and pathologists determine, during surgery, whether all the cancer has been removed.
Dr. Lola Reid is working with Tucker's cancer cells to determine where these cells start within the stem cells of the biliary tree. Dr. Reid has found a way to culture Tucker's cells and grow them to provide more cells for other labs' research. She is presently giving Tucker's cancer cells to immunosuppresed mice with the hope that a specific treatment option will result from her work. Dr. Reid has shared Tucker's cells with the National Institute of Health and Dr. Malcolm Moore at MSKCC.
Dr. Michael Torbenson has written the first paper on blood markers for fibrolamellar which was published in the journal, Modern Pathology, in late 2010. The article recognized FCF for their financial support. While at Johns Hopkins Dr. Torbenson was studying the microRNA of fibrolamellar cells and his laboratory was working on a genetic sequencing study of fibrolamellar to determine if there are genetic mutations unique to fibrolamellar cells. In 2013 Dr. Torbenson relocated to the Mayo Clinic in Rochester, MN.
Dr. Y.Z. Wang published his findings on the microRNA research he is doing on cancer. He has thanked FCF for supporting his effort. His findings will help other microRNA researchers who are studying other cancers, ie. Dr. Torbenson at Johns Hopkins University who is studying microRNA of fibrolamellar. Dr. Wang's paper sets an important precedent in cancer research in that it reports discrete molecular (microRNA) differences between tumors which metastasize and perfectly matched tumors that do not. These findings may have diagnostic, prognostic and most important of all, therapeutic implications.
CONTACT US • JOIN